ATE401901T1 - Antikrebs- und antivirale zusammensetzung - Google Patents

Antikrebs- und antivirale zusammensetzung

Info

Publication number
ATE401901T1
ATE401901T1 AT03759049T AT03759049T ATE401901T1 AT E401901 T1 ATE401901 T1 AT E401901T1 AT 03759049 T AT03759049 T AT 03759049T AT 03759049 T AT03759049 T AT 03759049T AT E401901 T1 ATE401901 T1 AT E401901T1
Authority
AT
Austria
Prior art keywords
anticancer
antiviral composition
composition
present
antiviral
Prior art date
Application number
AT03759049T
Other languages
English (en)
Inventor
Lae-Ok Park
Original Assignee
Lae-Ok Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020020067293A external-priority patent/KR100925516B1/ko
Priority claimed from KR1020020067291A external-priority patent/KR100932520B1/ko
Priority claimed from KR1020020081951A external-priority patent/KR100428587B1/ko
Priority claimed from KR1020030072732A external-priority patent/KR100428588B1/ko
Application filed by Lae-Ok Park filed Critical Lae-Ok Park
Application granted granted Critical
Publication of ATE401901T1 publication Critical patent/ATE401901T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
AT03759049T 2002-10-31 2003-10-31 Antikrebs- und antivirale zusammensetzung ATE401901T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR1020020067293A KR100925516B1 (ko) 2002-10-31 2002-10-31 아연 및 ｌ-아르기닌을 함유한 항암용 조성물
KR1020020067291A KR100932520B1 (ko) 2002-10-31 2002-10-31 항암제 조성물
KR1020020081951A KR100428587B1 (ko) 2002-12-20 2002-12-20 구연산, 아연 및 ｌ-아르기닌을 포함하는 항암제 조성물
KR1020030072732A KR100428588B1 (ko) 2003-10-17 2003-10-17 구연산, 아연 및 ｌ-아르기닌을 포함하는 항 바이러스제조성물

Publications (1)

Publication Number Publication Date
ATE401901T1 true ATE401901T1 (de) 2008-08-15

Family

ID=32234320

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03759049T ATE401901T1 (de) 2002-10-31 2003-10-31 Antikrebs- und antivirale zusammensetzung

Country Status (8)

Country Link
US (2) US20070166401A1 (de)
EP (1) EP1565195B1 (de)
JP (2) JP4603891B2 (de)
CN (1) CN1708310A (de)
AT (1) ATE401901T1 (de)
AU (1) AU2003274800A1 (de)
DE (1) DE60322415D1 (de)
WO (1) WO2004039379A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968122B2 (en) 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
KR100656807B1 (ko) * 2005-02-23 2006-12-13 배석년 구연산, 아연 및 아르기닌으로 이루어진 팽창선조 예방 및치료용 조성물
KR20090127925A (ko) * 2007-03-09 2009-12-14 마루이시세이야쿠가부시키가이샤 소독 방법 및 소독용 조성물
WO2012087113A1 (en) * 2010-12-24 2012-06-28 N.V. Nutricia Improved nutritional tablet
KR20140026372A (ko) 2011-02-02 2014-03-05 이무노퓨처 아이앤씨. 혈액-뇌 장벽을 투과하는 약물 전달체, 펩티드 및 이의 용도
KR101546802B1 (ko) * 2013-06-12 2015-08-24 박래옥 붕산, 구연산, 아연, 알부민 및 비타민 c를 포함하는 파필로마 바이러스에 대한 항바이러스 피부외용제 조성물
WO2019000163A1 (zh) * 2017-06-26 2019-01-03 余祖江 精氨酸在制备抗肿瘤药物中的用途
WO2019142490A1 (ja) * 2018-01-19 2019-07-25 Ｄｅｌｔａ－Ｆｌｙ Ｐｈａｒｍａ株式会社 がん患者の治療に有用な尿のアルカリ剤
KR102155802B1 (ko) * 2018-09-21 2020-09-14 박래옥 시트르산 및 아르기닌 포함 아연 착화합물
WO2021211660A1 (en) * 2020-04-14 2021-10-21 Vector Vitale Ip Llc Method of preventing or treating viral infections
EP4125851B1 (de) * 2020-10-27 2025-06-18 Gosbert Weth Antivirale thrombosehemmende zusammensetzung zur verwendung bei der behandlung von covid-19 enthaltend arginin und thiocyanat
US12414928B2 (en) 2021-05-14 2025-09-16 Rene Dumalaog Javier Viral inactivation spray and gargling formulation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3697287A (en) * 1969-01-28 1972-10-10 Morton Norwich Products Inc Amino acid food composition
GB8410403D0 (en) * 1984-04-24 1984-05-31 Unilever Plc Antiperspirant product
US5599551A (en) * 1989-06-06 1997-02-04 Kelly; Patrick D. Genital lubricants containing zinc as an anti-viral agent
AU7148791A (en) * 1989-12-29 1991-07-24 Mcgaw, Inc. The use of arginine as an immunostimulator
KR930002831B1 (ko) * 1990-12-04 1993-04-10 일양약품 주식회사 항종양 면역증강효과가 있는 단백다당체(c 909)
JPH08504837A (ja) * 1993-10-14 1996-05-28 生化学工業株式会社 新規ポリペプチドおよびこれから調製される抗ｈｉｖ剤
US6238682B1 (en) * 1993-12-13 2001-05-29 The Procter & Gamble Company Anhydrous skin lotions having antimicrobial components for application to tissue paper products which mitigate the potential for skin irritation
US5719133A (en) * 1994-09-21 1998-02-17 Novartis Nutrition Ag Adolescent dietary composition
JP2000212088A (ja) * 1999-01-27 2000-08-02 Kobayashi Kako Kk 難溶性抗ウイルス剤の水溶液
GB2359021B (en) * 2000-02-09 2002-04-24 Andromeda Trading Ltd Method and composition for promoting hair growth
KR20030021857A (ko) * 2001-09-08 2003-03-15 주식회사 에코윈 아미노산 음이온-제2구리 착물을 포함하는 항암제 및 이의제조방법
JP4323128B2 (ja) * 2002-01-16 2009-09-02 正 五井野 生理活性組成物
AU2003215935A1 (en) * 2002-03-16 2003-09-29 Seog-Nyeon Bae Anticancer composition
KR100426450B1 (ko) * 2002-03-16 2004-04-13 박래옥 구연산, 알부민 및 아연을 함유한 항암 조성물

Also Published As

Publication number Publication date
EP1565195B1 (de) 2008-07-23
US20090226538A1 (en) 2009-09-10
US20070166401A1 (en) 2007-07-19
JP2006506400A (ja) 2006-02-23
JP5232103B2 (ja) 2013-07-10
EP1565195A4 (de) 2006-05-10
AU2003274800A1 (en) 2004-05-25
DE60322415D1 (de) 2008-09-04
JP2009298800A (ja) 2009-12-24
CN1708310A (zh) 2005-12-14
JP4603891B2 (ja) 2010-12-22
WO2004039379A1 (en) 2004-05-13
EP1565195A1 (de) 2005-08-24

Similar Documents

Publication Publication Date Title
WO2021262826A3 (en) 1'-cyano nucleoside analogs and uses thereof
WO2002014311A3 (en) Urea compounds and methods of uses
CY1107853T1 (el) Χρησεις αντισπασμωδικων αμινοξεων για τη θεραπευτικη αγωγη διπολικων διαταραχων
MXPA04012965A (es) Inhibidores virales.
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
EA201000643A1 (ru) Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
MY177111A (en) Substituted amide derivatives and methods of use
AUPR213700A0 (en) Antiviral agents
BRPI0411900B8 (pt) compostos e composições farmacêuticas compreendendo os mesmos
WO2004005279A3 (en) Substituted anthranilic amide derivatives and methods of use
SG149067A1 (en) IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT
SG163517A1 (en) Antiviral compounds and methods
SG148177A1 (en) Novel cis-imidazolines
ATE401901T1 (de) Antikrebs- und antivirale zusammensetzung
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
WO2024076951A3 (en) Antiviral prodrugs and formulations thereof
ATE339198T1 (de) Verwendung von 2-amino-2-(2-(4- octylphenyl)ethyl)propane-1,3-diol zur prävention oder behandlung viraler myocarditis
ECSP055844A (es) Nuevos compuestos triciclicos
WO2002062322A3 (en) Glycine betaine and its use as anti-hemorrhagic agent
UA42719C2 (uk) Сполуки, композиції та способи, які інгібують протеази, для лікування та профілактики імуномедіаторних запальних хвороб
EA200501344A1 (ru) Комбинированное применение рибавирина и бета-интерферона при демиелинизирующих заболеваниях
EP2593460A4 (de) 7,9-stickstoff-radikal-4-oxo-4h-pyrido-[l,2-a-] pyrimidin-2-carboxylsäure-benzylamid-virostatika
ATE393624T1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
EP1868613A4 (de) Polymorphe von 3-o-(3',3'-dimethylsuccinyl)betulinsäure-di-n-methyl-d-glucamin
EA200601666A1 (ru) Комбинированная фармацевтическая композиция для ингибирования ухудшения когнитивных функций

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties